Clinical Trial Update: The Rifaximin Study in CVID [Phase 4]

View source ↗

Summary

This update reports the completion of a Phase 4 clinical trial evaluating rifaximin in patients with Common Variable Immunodeficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Variable Immunodeficiency

Drugs mentioned

• XIFAXAN (rifaximin)

Snippet

Sponsor: Oslo University Hospital | Conditions: Common Variable Immunodeficiency (CVID) | Phase 4 | Status: COMPLETED